Spyre Therapeutics, Inc. Commitments Disclosure
15. Commitments and Contingencies
The Company leases office and laboratory space in Austin, Texas under operating leases that commenced in January 2015 and February 2017, respectively. The office lease was amended in September 2016 to increase office space and extend the term to December 31, 2020. In addition, the amended office lease provides for tenant improvement allowances on both the original space and expansion space totaling $0.2 million.
The Company signed a new laboratory lease agreement in October 2017 for the original laboratory space, which commenced on January 1, 2018. The laboratory lease was subsequently amended in October 2018 to increase the space and extend the lease term to September 30, 2021.
As provided in the office and laboratory leases, monthly lease payments are subject to annual increases through the lease term. The Company recognizes rent expense on a straight-line basis over the non-cancellable term of each lease.
The Company is subject to security deposit requirements under the terms of the amended office lease and laboratory lease agreements, totaling $48,000, until the expiration of the lease. The lessor is entitled to retain all or any part of the security deposit for payment in the event of any uncured default by the Company under the terms of the lease.
Future annual minimum lease payments due under non-cancellable operating leases at December 31 of each year are as follows (in thousands):
|
2019 |
|
$ |
397 |
|
|
2020 |
|
|
409 |
|
|
2021 |
|
|
83 |
|
|
Thereafter |
|
|
— |
|
|
Total minimum lease payments |
|
$ |
889 |
|
For the years ended December 31, 2018, 2017, and 2016, the Company incurred $0.4 million, $0.4 million, and $0.2 million in rent expense under non-cancellable operating leases.
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2018 | Mar 7, 2019 | Showing above |
| 2017 | Mar 13, 2018 | |
| 2016 | Mar 23, 2017 | |
About Commitments Disclosures
Commitments and contingencies disclosures catalog a company's off-balance-sheet obligations and legal exposures — purchase commitments, guarantee arrangements, pending litigation, and regulatory proceedings. These items represent potential future cash outflows that may not appear as liabilities on the balance sheet until they become probable and estimable.
Key signals: litigation reserves and disclosed loss ranges quantify management's estimate of legal exposure, but unquantified "reasonably possible" losses often represent the larger risk. Watch for changes in language around pending cases — shifts from "remote" to "reasonably possible" or increases in estimated loss ranges signal deteriorating outcomes. Unconditional purchase obligations and take-or-pay contracts create fixed cost structures that reduce operational flexibility. Guarantee arrangements for subsidiaries or joint ventures can create cascading obligations. Compare the total commitment schedule against projected free cash flow to assess whether the company can meet its obligations without additional financing.